A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection
Details
Download: REF.pdf (281.30 [Ko])
State: Public
Version: Final published version
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
State: Public
Version: Final published version
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_BFC47D7BCC54
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection
Journal
Clinical Infectious Diseases
ISSN
1537-6591 (Electronic)
Publication state
Published
Issued date
11/2004
Volume
39
Number
9
Pages
1285-92
Notes
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Nov 1
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Nov 1
Abstract
BACKGROUND: Oral combination therapy with fluoroquinolones plus rifampicin is a promising alternative to standard parenteral therapy for staphylococcal infections. METHODS: In a multicenter, randomized trial, we compared the efficacy, safety, and length of hospital stay for patients with staphylococcal infections treated either with an oral combination of a fluoroquinolone (fleroxacin) plus rifampicin or with standard parenteral treatment (flucloxacillin or vancomycin). Patients were included if cultures showed the presence of bacteremia or deep-seated infections with Staphylococcus aureus (104 patients) or catheter-related bacteremia due to drug-susceptible, coagulase-negative staphylococci (23 patients). RESULTS: The cure rate in the intention-to-treat analysis was 78% for the fleroxacin-rifampicin group (68 patients) and 75% for the standard therapy group (59 patients; 47 received flucloxacillin, and 12 received vancomycin); in the population of clinically evaluable patients (n=119), the cure rate was 82% and 80%, respectively; and in the population of microbiologically evaluable patients (n=103), the cure rate was 86% and 84%, respectively. Clinical and bacteriological failures after S. aureus infections were documented in similar proportions of patients. The median length of hospital stay after study entry was 12 days in the fleroxacin-rifampicin group, compared with 23 days in the standard treatment group (P=.006). More adverse events probably related to the study drug were reported in the fleroxacin-rifampicin group than in the standard therapy group (15 of 68 vs. 5 of 59 patients; P=.05). CONCLUSIONS: This study suggests that an oral regimen containing a fluoroquinolone plus rifampicin may be effective for treating staphylococcal infections, allowing earlier discharge from the hospital.
Keywords
Administration, Oral
Adult
Aged
Bacteremia/drug therapy
Catheters, Indwelling/microbiology
Drug Therapy, Combination
Female
Fleroxacin/administration & dosage/adverse effects/*therapeutic use
Floxacillin/administration & dosage/adverse effects/*therapeutic use
Humans
Male
Methicillin Resistance/drug effects
Middle Aged
Prospective Studies
Rifampin/administration & dosage/adverse effects/*therapeutic use
Safety
Staphylococcal Infections/diagnosis/*drug therapy/metabolism
Staphylococcus/drug effects/isolation & purification
Staphylococcus aureus/drug effects/isolation & purification
Treatment Outcome
Vancomycin/administration & dosage/adverse effects/*therapeutic use
Pubmed
Web of science
Open Access
Yes
Create date
25/01/2008 17:07
Last modification date
14/02/2022 7:56